We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has reversed a $1.2 billion ruling which found Gilead Sciences’ cancer immunotherapy Yescarta (axicabtagene ciloleucel) infringed on a Bristol Myers Squibb (BMS) patent for CAR-T technology. Read More
In addition to potential Alzheimer’s and Parkinson’s therapies, Shape said it may use its adeno-associated virus platform to help identify other gene therapy targets, including for rare diseases. Read More
South Korean conglomerate Samsung, which already manufactures Moderna’s COVID-19 vaccine, plans to increase its involvement in the biopharmaceuticals space. Read More
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said. Read More
Eli Lilly’s biologics division, Lilly Bio-Medicines, is splitting into two distinct units, one of which will focus entirely on approved and phase 3 drugs for pain and neurodegeneration — including Alzheimer’s disease. Read More
There’s no national shortage of the life-saving opiate antagonist naloxone — just a shortage of the free or cheap single-use vials that Pfizer has distributed by the millions since 2017. Read More